AR013746A1 - Sustitucion bioisosterica de catecol por indazol en compuesto terapeuticos activos - Google Patents
Sustitucion bioisosterica de catecol por indazol en compuesto terapeuticos activosInfo
- Publication number
- AR013746A1 AR013746A1 ARP980105534A ARP980105534A AR013746A1 AR 013746 A1 AR013746 A1 AR 013746A1 AR P980105534 A ARP980105534 A AR P980105534A AR P980105534 A ARP980105534 A AR P980105534A AR 013746 A1 AR013746 A1 AR 013746A1
- Authority
- AR
- Argentina
- Prior art keywords
- catechol
- activity
- compounds
- indazole
- substituents
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 230000001225 therapeutic effect Effects 0.000 title abstract 5
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 102000003914 Cholinesterases Human genes 0.000 abstract 1
- 108090000322 Cholinesterases Proteins 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 239000000332 adrenergic beta-1 receptor antagonist Substances 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 229940048961 cholinesterase Drugs 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones terapéuticamente activas de materia y tipos de miembros de las mismas que comprenden compuestos que contienen indazol, resultando dichoscompuestos y su actividad terapéutica directamente de una sustitucion bioisostérica decatecol por indazol de un compuesto que contiene catecol quetiene dicha actividad terapéutica, donde los substituyentes no catecol son los mismos u homologos antes y después de dicha sustitucion, en la que dichascomposiciones de materia comprenden un compuesto de formula (I1) o I2) o una sal farmacéuticamente aceptable del mismo, en la que en una realizacionpreferida Rc es hidrogeno, RA es ciclohexilo, y RB es etilo. Ra y Rb son cada uno de ellos individual e independientemente hidrogeno o substituyentesno catecol de dichos compuestos que se producen directamente de una sustitucion bioisostérica de catecol por indazol de dicho compuesto quecontiene catecol que tiene dicha actividad terapéutica, donde dichossubstituyentes no catecol son los mismos u homologos antes y después de dichasustitucion, con la condicion de que Ra y Rb no sean hidrogeno al mismo tiempo. La actividad terapéutica involucrada comprende una actividad inhibidorade la colinesterasa, una actividad antagonista Alfa1-adrenérgica y agonista- beta1-adrenérgica, una actividad inhibidora del canal de calcio, unaactividad antineoplásica y una actividad inhibidora de la fosfodiesterasa de tipo IV.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6402497P | 1997-11-04 | 1997-11-04 | |
| US6418797P | 1997-11-04 | 1997-11-04 | |
| US6422997P | 1997-11-04 | 1997-11-04 | |
| US6422897P | 1997-11-04 | 1997-11-04 | |
| US6419897P | 1997-11-04 | 1997-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013746A1 true AR013746A1 (es) | 2001-01-10 |
Family
ID=27535645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105534A AR013746A1 (es) | 1997-11-04 | 1998-11-03 | Sustitucion bioisosterica de catecol por indazol en compuesto terapeuticos activos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6391872B1 (es) |
| EP (1) | EP1028946A1 (es) |
| JP (1) | JP2001521926A (es) |
| CN (1) | CN1284948A (es) |
| AP (1) | AP910A (es) |
| AR (1) | AR013746A1 (es) |
| AU (1) | AU754734B2 (es) |
| BG (1) | BG104450A (es) |
| BR (1) | BR9813926A (es) |
| CA (1) | CA2309150A1 (es) |
| CZ (1) | CZ20001621A3 (es) |
| DZ (1) | DZ2640A1 (es) |
| EA (1) | EA200000488A1 (es) |
| HR (1) | HRP20000253A2 (es) |
| HU (1) | HUP0004150A3 (es) |
| ID (1) | ID23921A (es) |
| IL (1) | IL135900A0 (es) |
| IS (1) | IS5465A (es) |
| MA (1) | MA26563A1 (es) |
| NO (1) | NO20002129L (es) |
| NZ (1) | NZ503918A (es) |
| OA (1) | OA11354A (es) |
| PE (1) | PE129199A1 (es) |
| PL (1) | PL340753A1 (es) |
| SK (1) | SK6252000A3 (es) |
| TN (1) | TNSN98200A1 (es) |
| TR (1) | TR200001234T2 (es) |
| WO (1) | WO1999023077A1 (es) |
| YU (1) | YU25000A (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200000385A1 (ru) * | 1997-11-04 | 2000-10-30 | Пфайзер Продактс Инк. | Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4) |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| JP2001031549A (ja) * | 1999-07-14 | 2001-02-06 | Pola Chem Ind Inc | 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料 |
| ATE341341T1 (de) * | 1999-08-12 | 2006-10-15 | Wyeth Corp | Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs |
| US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| US7005443B1 (en) * | 2000-03-17 | 2006-02-28 | Alcon, Inc. | 5-Hydroxy indazole derivatives for treating glaucoma |
| CA2398446A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
| CA2440842A1 (en) | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Novel 1h-indazole compounds |
| AU2002337105B2 (en) | 2001-09-19 | 2008-03-20 | Takeda Gmbh | Combination of a NSAID and a PDE-4 inhibitor |
| WO2003024456A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating and preventing migraines |
| KR20040085179A (ko) * | 2002-02-13 | 2004-10-07 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 통합된 반도체 광학 디바이스, 이러한 디바이스를제조하는 방법 및 장치 |
| US7972632B2 (en) | 2003-02-28 | 2011-07-05 | Unigen Pharmaceuticals, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| US7108868B2 (en) | 2002-03-22 | 2006-09-19 | Unigen Pharmaceuticals, Inc. | Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia |
| US8034387B2 (en) | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| KR100621234B1 (ko) * | 2002-04-30 | 2006-09-13 | 유니젠 파아마슈티컬스,인크. | 치료제로서 프리-비-링 플라보노이드와 플라반 혼합물의제형 |
| WO2004050634A1 (en) | 2002-12-02 | 2004-06-17 | F. Hoffmann-La Roche Ag | Indazole derivatives as crf antagonists |
| KR20050101551A (ko) * | 2003-02-14 | 2005-10-24 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP4769184B2 (ja) * | 2003-04-04 | 2011-09-07 | ユニジェン・インコーポレーテッド | 哺乳動物の皮膚のケアのためのシクロオキシゲナーゼ（ｃｏｘ）およびリポキシゲナーゼ（ｌｏｘ）の二重の阻害薬の製剤 |
| US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
| EP1720878A1 (en) | 2004-02-27 | 2006-11-15 | F.Hoffmann-La Roche Ag | Heteroaryl-fused pyrazolo derivatives |
| JP2007523937A (ja) | 2004-02-27 | 2007-08-23 | エフ．ホフマン−ラ ロシュ アーゲー | インダゾール誘導体およびそれを含む医薬組成物 |
| CN1926139A (zh) | 2004-02-27 | 2007-03-07 | 霍夫曼-拉罗奇有限公司 | 稠合吡唑衍生物 |
| US7844309B2 (en) * | 2004-02-27 | 2010-11-30 | Nokia Corporation | Exchangeable keymat |
| US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
| AP2007004024A0 (en) * | 2004-11-29 | 2007-06-30 | Warner Lambert Co | Therapeutic pyrazoloÄ3,4-BÜpyridines and indazoles |
| CN101282938A (zh) * | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
| RU2008103700A (ru) * | 2005-08-15 | 2009-09-27 | Вайет (Us) | Производные азинил-3-сульфонилиндазола в качестве лиганд 5ов 5-гидрокситриптамина-6 |
| WO2007023111A2 (en) | 2005-08-25 | 2007-03-01 | F. Hoffmann-La Roche Ag | P38 map kinase inhibitors and methods for using the same |
| EP1928866A1 (en) | 2005-09-05 | 2008-06-11 | Ranbaxy Laboratories Limited | Substituted indazoles as inhibitors of phosphodiesterase type-iv |
| US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| EP2628725A1 (en) * | 2005-11-03 | 2013-08-21 | Allergan, Inc. | Prostaglandins and analogues as agents for lowering intraocular pressure |
| MX2008009022A (es) | 2006-01-13 | 2008-09-24 | Wyeth Corp | 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina. |
| PL1981851T3 (pl) | 2006-01-31 | 2012-07-31 | Array Biopharma Inc | Inhibitory kinazy i sposoby ich stosowania |
| AU2007221021B2 (en) | 2006-02-28 | 2013-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic piperazines as PDE4 inhibitors |
| US8084485B2 (en) | 2006-03-31 | 2011-12-27 | Vitae Pharmaceuticals, Inc. | 6-(aminoalkyl)indazoles |
| EP2001865A1 (en) * | 2006-04-05 | 2008-12-17 | Wyeth a Corporation of the State of Delaware | Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands |
| WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| US8012886B2 (en) * | 2007-03-07 | 2011-09-06 | Asm Assembly Materials Ltd | Leadframe treatment for enhancing adhesion of encapsulant thereto |
| DK2124944T3 (da) | 2007-03-14 | 2012-04-23 | Ranbaxy Lab Ltd | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer |
| CN102648284B (zh) * | 2009-09-18 | 2014-09-24 | 株式会社里维松 | 多酚衍生物及其制造方法 |
| US8293738B2 (en) | 2010-05-12 | 2012-10-23 | Abbott Laboratories | Indazole inhibitors of kinase |
| CN103709146B (zh) * | 2014-01-15 | 2015-11-25 | 中国药科大学 | 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CA3205986A1 (en) | 2020-12-30 | 2022-07-07 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003385A1 (fr) * | 1987-10-13 | 1989-04-20 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de pyrazole fusionnes, procede de preparation et utilisation en medecine |
| EP0338087A4 (en) * | 1987-10-13 | 1991-07-24 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrazole compounds, process for their preparation, and their medicinal use |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| AP2001002304A0 (en) * | 1996-05-03 | 2001-12-31 | Pfizer | Substituted indazole derivatives and related compounds |
| ES2201299T3 (es) * | 1996-06-25 | 2004-03-16 | Pfizer Inc. | Derivados sustituidos de indazol y su uso como inhibidores de fosfodiesterasa (pde) de tipo iv y factor de necrosis tumoral (tnf)`. |
| DE69709493T2 (de) * | 1996-06-27 | 2002-10-31 | Pfizer Inc., New York | Substituierte Indazolderivate |
| BR9712005A (pt) * | 1996-09-04 | 1999-08-24 | Pfizer | Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf) |
| EA200000385A1 (ru) * | 1997-11-04 | 2000-10-30 | Пфайзер Продактс Инк. | Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4) |
-
1998
- 1998-10-26 EA EA200000488A patent/EA200000488A1/ru unknown
- 1998-10-26 EP EP98947732A patent/EP1028946A1/en not_active Withdrawn
- 1998-10-26 YU YU25000A patent/YU25000A/sh unknown
- 1998-10-26 CZ CZ20001621A patent/CZ20001621A3/cs unknown
- 1998-10-26 TR TR2000/01234T patent/TR200001234T2/xx unknown
- 1998-10-26 HR HR20000253A patent/HRP20000253A2/hr not_active Application Discontinuation
- 1998-10-26 BR BR9813926-6A patent/BR9813926A/pt not_active IP Right Cessation
- 1998-10-26 US US09/381,425 patent/US6391872B1/en not_active Expired - Fee Related
- 1998-10-26 NZ NZ503918A patent/NZ503918A/en unknown
- 1998-10-26 SK SK625-2000A patent/SK6252000A3/sk unknown
- 1998-10-26 CN CN98812929A patent/CN1284948A/zh active Pending
- 1998-10-26 ID IDW20000819A patent/ID23921A/id unknown
- 1998-10-26 CA CA002309150A patent/CA2309150A1/en not_active Abandoned
- 1998-10-26 WO PCT/IB1998/001710 patent/WO1999023077A1/en not_active Ceased
- 1998-10-26 JP JP2000518952A patent/JP2001521926A/ja active Pending
- 1998-10-26 AU AU94552/98A patent/AU754734B2/en not_active Ceased
- 1998-10-26 PL PL98340753A patent/PL340753A1/xx not_active Application Discontinuation
- 1998-10-26 HU HU0004150A patent/HUP0004150A3/hu unknown
- 1998-10-26 IL IL13590098A patent/IL135900A0/xx unknown
- 1998-10-29 AP APAP/P/1998/001375A patent/AP910A/en active
- 1998-11-03 AR ARP980105534A patent/AR013746A1/es not_active Application Discontinuation
- 1998-11-03 PE PE1998001041A patent/PE129199A1/es not_active Application Discontinuation
- 1998-11-03 TN TNTNSN98200A patent/TNSN98200A1/fr unknown
- 1998-11-03 MA MA25332A patent/MA26563A1/fr unknown
- 1998-11-03 DZ DZ980250A patent/DZ2640A1/xx active
-
2000
- 2000-04-19 IS IS5465A patent/IS5465A/is unknown
- 2000-04-26 NO NO20002129A patent/NO20002129L/no not_active Application Discontinuation
- 2000-04-28 OA OA1200000127A patent/OA11354A/en unknown
- 2000-05-17 BG BG104450A patent/BG104450A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE129199A1 (es) | 1999-12-16 |
| DZ2640A1 (fr) | 2003-03-08 |
| NZ503918A (en) | 2002-03-28 |
| ID23921A (id) | 2000-05-25 |
| JP2001521926A (ja) | 2001-11-13 |
| HRP20000253A2 (en) | 2001-06-30 |
| OA11354A (en) | 2003-12-23 |
| US6391872B1 (en) | 2002-05-21 |
| YU25000A (sh) | 2003-12-31 |
| WO1999023077A1 (en) | 1999-05-14 |
| TNSN98200A1 (fr) | 2005-03-15 |
| TR200001234T2 (tr) | 2000-08-21 |
| EP1028946A1 (en) | 2000-08-23 |
| NO20002129D0 (no) | 2000-04-26 |
| AU754734B2 (en) | 2002-11-21 |
| CN1284948A (zh) | 2001-02-21 |
| PL340753A1 (en) | 2001-02-26 |
| AP910A (en) | 2000-12-05 |
| HUP0004150A2 (hu) | 2001-05-28 |
| CZ20001621A3 (cs) | 2001-08-15 |
| BG104450A (en) | 2000-12-29 |
| HUP0004150A3 (en) | 2001-08-28 |
| IL135900A0 (en) | 2001-05-20 |
| CA2309150A1 (en) | 1999-05-14 |
| EA200000488A1 (ru) | 2000-10-30 |
| SK6252000A3 (en) | 2001-11-06 |
| BR9813926A (pt) | 2000-09-19 |
| MA26563A1 (fr) | 2004-12-20 |
| IS5465A (is) | 2000-04-19 |
| AP9801375A0 (en) | 1998-12-31 |
| AU9455298A (en) | 1999-05-24 |
| NO20002129L (no) | 2000-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013746A1 (es) | Sustitucion bioisosterica de catecol por indazol en compuesto terapeuticos activos | |
| NO20021328L (no) | Pyrazolopyrimidier som terapeutiske midler | |
| ES2121896T3 (es) | Derivados de acido hidroxamico como inhibidores de colagenasa. | |
| ES2153907T3 (es) | Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d. | |
| EA199800184A1 (ru) | Соединение бензимидазола | |
| DK0562956T3 (da) | Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem | |
| ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
| DK165447C (da) | 2-pyrimidinyl-1-piperazin-derivater, fremgangsmaader til deres fremstilling og laegemidler indeholdende dem | |
| DK0750618T3 (da) | Oxazolidinonderivater og farmaceutiske præparater indeholdende dem | |
| UY27370A1 (es) | Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células y métodos para su utilización | |
| ES2164920T3 (es) | Nuevos derivados heterociclicos y uso medicinal de los mismos. | |
| DK1226148T3 (da) | Hidtil ukendte oligosaccharider, fremstilling heraf og farmaceutiske præparater, der indeholder dem | |
| CO5580767A2 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
| NO990433L (no) | Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet | |
| MX9301197A (es) | Derivados de indol. | |
| NO20020282L (no) | Nytt difenyl-piperidinderivat | |
| MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| MX9301527A (es) | Composiciones de acido n-(fosfonoacetil)-l-aspartico y metodo para sus usos como agentes antivirales de amplio espectro. | |
| DK1109560T3 (da) | Som AICARFT-inhibitorer anvendelige forbindelser | |
| ES2123499T3 (es) | Metodos y composiciones para tratamiento de infecciones virales. | |
| ATE253359T1 (de) | Antithrombotische mittel | |
| AR014146A1 (es) | Compuestos de triazina, su uso en terapia, composiciones farmaceuticas que los contienen, proceso para su manufactura e intermediarios de sintesis | |
| ECSP982722A (es) | Sustitucion bioisosterica de catecol por indazol en compuestos terapeuticamente activos | |
| ES2149193T3 (es) | Compuestos heterociclicos sustituidos con alquilo. | |
| NO991589L (no) | Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |